^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    SETD2 overexpression

    i
    Other names: SETD2, SET Domain Containing 2, Histone Lysine Methyltransferase, HIF-1, KMT3A, HYPB, Histone-Lysine N-Methyltransferase SETD2, Protein-Lysine N-Methyltransferase SETD2, Huntingtin-Interacting Protein B, Lysine N-Methyltransferase 3A, Huntingtin Yeast Partner B, SET Domain Containing 2, KIAA1732, P231HBP, HIP-1, SET2, Huntingtin Interacting Protein 1, Huntingtin-Interacting Protein 1, SET Domain-Containing Protein 2, FLJ23184, HSPC069, HBP231, SETD2, HSET2, HIF1, LLS
    Entrez ID:
    29072
    Related biomarkers:
    Mutation
    CNA
    Fusion
    Others
    26d
    Exploring The Prognostic Significance of SET-Domain Containing 2 (SETD2) Expression in Advanced and Castrate-Resistant Prostate Cancer. (PubMed, Cancers (Basel))
    We also investigated the protein expression database TCPA, and our results showed that high SETD2 expression is associated with a poor prognosis. Finally, we performed TCGA PRAD gene set enrichment analysis (GSEA) data for SETD2 overexpression, and our data revealed a potential association with pathways involved in tumor progression such as the AMPK signaling pathway, the cAMP signaling pathway, and the PI3K-Akt signaling pathway, which are potentially associated with tumor progression, chemoresistance, and a poor prognosis.
    Journal • Metastases
    |
    PTEN (Phosphatase and tensin homolog) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase)
    |
    ER positive • SETD2 overexpression